Edition:
India

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

21.11USD
9:19pm IST
Change (% chg)

$-0.31 (-1.45%)
Prev Close
$21.42
Open
$21.28
Day's High
$21.37
Day's Low
$20.83
Volume
175,147
Avg. Vol
875,365
52-wk High
$32.49
52-wk Low
$18.04

Chart for

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 1.90
Market Cap(Mil.): $7,556.29
Shares Outstanding(Mil.): 293.90
Dividend: --
Yield (%): --

Financials

BRIEF-Exelixis Says CEO Michael Morrissey's FY 2017 Total Compensation Was $9.4 Mln VS $6.3 Mln

* EXELIXIS INC SAYS CEO MICHAEL MORRISSEY'S FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $6.3 MLN IN 2016 - SEC FILING Source text: (https://bit.ly/2Hi8UXj) Further company coverage:

12 Apr 2018

BRIEF-Exelixis Says Board Increased Size Of Board To 12 Members

* EXELIXIS SAYS BOARD INCREASED SIZE OF BOARD TO 12 MEMBERS - SEC FILING Source text: (https://bit.ly/2uWDtwR) Further company coverage:

10 Apr 2018

BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx

* EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

28 Mar 2018

BRIEF-Exelixis' Partner Ipsen Announces Positive CHMP Opinion For Cabometyx

* EXELIXIS' PARTNER IPSEN ANNOUNCES POSITIVE CHMP OPINION FOR CABOMETYX FOR PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA​

23 Mar 2018

BRIEF-Exelixis Submits U.S. Supplemental NDA For Cabometyx

* EXELIXIS SUBMITS U.S. SUPPLEMENTAL NEW DRUG APPLICATION FOR CABOMETYX (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

15 Mar 2018

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​

27 Feb 2018

BRIEF-Exelixis Posts Q4 Earnings Per Share $0.12

* EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

27 Feb 2018

BRIEF-Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA

14 Feb 2018

BRIEF-Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib

* EXELIXIS ANNOUNCES UPDATED PHASE 1 TRIAL RESULTS FOR CABOZANTINIB IN COMBINATION WITH NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN REFRACTORY GENITOURINARY (GU) TUMORS Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

17 Jan 2018

Competitors

Earnings vs. Estimates